Digital health care unicorns look to 2025

3 key issues to watch at the FDA

December 31, 2024 Check out STAT+

Sponsored By

Photo illustration: Christine Kao/STAT; Photos courtesy: Omada Health, XTR, Hinge Health, Maven Clinic STAT+ | Four digital health unicorns on what they expect in 2025 Top executives at Omada, Transcarent, Hinge Health, and Maven Clinic reflect on the year that passed, and the year ahead for their companies. By Mario Aguilar STAT+ | 3 key issues to watch at the FDA as Trump takes office STAT '3 to Watch' series looks at key FDA issues for 2025: New rules for ultraprocessed foods, drug user fees, and regulating AI, lab-developed tests. By Lizzy Lawrence STAT+ | Pfizer kills hemophilia gene therapy deal, imperiling Sangamo Sangamo, a gene therapy pioneer, loses a financial lifeline despite positive Phase 3 results for hemophilia treatment. By Jason Mast Christine Kao/STAT Opinion: The most read First Opinion essays of 2024 A wide range of authors contribute to STAT First Opinion: physicians, advocates, journalists, researchers. Here are 2024's top health and medicine essays. By Torie Bosch

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser